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Abstract: Women and couples continue to experience unintended pregnancies at high rates. In 
the US, 45% of all pregnancies are either mistimed or unwanted. Mishaps with contraceptives, 
such as condom breakage, missed pills, incorrect timing of patch or vaginal ring application, 
contraceptive nonuse, forced intercourse, and other circumstances, place women at risk of 
unintended pregnancy. There is a critical role for emergency contraception (EC) in preventing 
those pregnancies. There are currently three methods of EC available in the US. Levonorgestrel 
EC pills have been available with a prescription for over 15 years and over-the-counter since 
2013. In 2010, ulipristal acetate EC pills became available with a prescription. Finally, the 
copper intrauterine device remains the most effective form of EC. Use of EC is increasing over 
time, due to wider availability and accessibility of EC methods. One strategy to expand access 
for both prescription and nonprescription EC products is to include pharmacies as a point of 
access and allow pharmacist prescribing. In eight states, pharmacists are able to prescribe and 
provide EC directly to women: levonorgestrel EC in eight states and ulipristal acetate in seven 
states. In addition to access with a prescription written by a pharmacist or other health care 
provider, levonorgestrel EC is available over-the-counter in pharmacies and grocery stores. 
Pharmacists play a critical role in access to EC in community pharmacies by ensuring product 
availability in the inventory, up-to-date knowledge, and comprehensive patient counseling. 
Looking to the future, there are opportunities to expand access to EC in pharmacies further 
by implementing legislation expanding the pharmacist scope of practice, ensuring third-party 
reimbursement for clinical services delivered by pharmacists, and including EC in pharmacy 
education and training.
Keywords: pharmacist, community pharmacy, emergency contraception, levonorgestrel, uli-
pristal acetate, intrauterine device
Introduction
Women and couples continue to experience unintended pregnancies at high rates. In 
the US, 45% of all pregnancies are unintended, either mistimed or unwanted.1 Nearly 
all (95%) of unintended pregnancies are due to nonuse or incorrect/inconsistent use 
of contraception.2
Condoms and oral contraceptive pills remain the most commonly used methods of 
contraception in the US, with typical use-failure rates of 18% and 9%, respectively, 
in the first year of use.3 Both of these commonly used contraceptive methods have 
potential for mishaps, such as condom breakage and missed pills. Such mishaps as 
these, in addition to contraceptive nonuse, forced intercourse, and other circumstances, 
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place women at risk of unintended pregnancy. There is a 
critical role for emergency contraception (EC) in preventing 
unintended pregnancies.
EC is any form of contraception, hormonal or nonhor-
monal, that prevents pregnancy after sexual intercourse. 
There are currently two methods of EC approved by the US 
Food and Drug Administration (FDA) and a third that is used 
off-label (see Table 1). Previously, there was a dedicated 
combination EC product and some combination oral con-
traceptives used in larger doses for EC, known as the Yuzpe 
regimen. The Yuzpe regimen fell out of favor, because it 
was less effective than methods available currently and was 
associated with increased adverse effects, such as nausea, 
vomiting, and breast tenderness.
Use of EC is increasing over time, due to wider avail-
ability and accessibility of EC methods. Whereas only 1% of 
women of reproductive age had ever used EC in 1995, 11% 
had as of 2006–2010.4 Among women who have used EC, 
most (59%) have only used it once, 24% have used it twice, 
and 17% have used it three or more times.4 EC users are more 
likely to be young, never married, and have some college 
education.4 Similarly, in the last decade, EC use has increased 
from 8% of teens in 2002 to 22% of teens in 2011–2013.5 A 
recent study among uninsured adolescents found a high rate 
of EC awareness and low EC knowledge.6 Increasing EC use 
is due in part to new products being approved (ie, ulipristal 
acetate [UPA]) and changing regulations on existing prod-
ucts, namely removal of age and identification restrictions 
for over-the-counter (OTC) levonorgestrel.
To increase knowledge and use of EC, one strategy uti-
lized has been expansion of access points for both prescrip-
tion and nonprescription products to include pharmacies. 
Direct access to prescription drugs from pharmacists is called 
pharmacist prescribing or pharmacy access. See explanations 
for the various models of access in Table 2. In eight states, 
pharmacists are able to prescribe and provide EC directly to 
women (Table 3). This paper aims to review the role of the 
community pharmacist in EC counseling and delivery in the 
US. Historical and current trends are reviewed, then future 
prospects and opportunities presented.
Trends
Levonorgestrel
The first dedicated progestin-only EC product was approved 
in the US in 1999 by the FDA. The effectiveness of levo-
norgestrel EC products for preventing pregnancies is up to 
89%, and is primarily thought to be due to the suppression 
of ovulation. Other possible mechanisms of action include 
thickening of cervical mucus and prevention of sperm trans-
port.7–9 Effectiveness is greater the sooner levonorgestrel 
EC is taken after unprotected intercourse, and declines with 
time.7,10 The first dedicated product consisted of two tablets of 
0.75 mg levonorgestrel, each to be taken 12 hours apart. Soon 
after FDA approval, the manufacturer pursued switching the 
Table 1 Overview of emergency contraception methods
Levonorgestrel Ulipristal Copper 
IUD
Time frame As per package 
labeling for up to 72 
hours, but off-label up 
to 120 hours
Up to 120 hours Up to 
120 hours
Dose 1.5 mg 30 mg 380 mm2
Effectivenessa 89% 94% 99%
Adverse 
effects 
(>10%)
Nausea, abdominal 
pain, fatigue, headache, 
menstrual bleeding 
changes, dizziness, 
breast tenderness
Headache, 
abdominal pain, 
nausea
Bleeding, 
pain
Drug 
interactions
None CYP3A4 inducers 
and progestin-
containing 
contraceptives 
reduce 
effectiveness
None
Access OTC or Rx Rx only Rx only, 
placed by 
trained 
clinician
Notes: aEffectiveness results vary between studies. These values are approximate.
Abbreviations: IUD, intrauterine device; OTC, over-the-counter; Rx, prescription.
Table 2 Models of access to emergency contraception in the US
Model Description
Prescription only Approved as a prescription drug by the FDA.
Pharmacist 
prescribing
Approved as a prescription drug by the FDA 
and available directly from a pharmacist without 
a prior prescription, either under a statewide 
authority or collaborative practice agreement 
with a prescriber. The pharmacist initiates the 
prescription, and can dispense the medication. 
This is a de facto category allowed by state laws, 
and not recognized by the FDA. Also known as 
pharmacist-initiated or pharmacy access.
Behind-the-counter Approved as a nonprescription drug by the 
FDA, but has additional restrictions requiring 
oversight by the pharmacy, such as identification 
requirements or sex or age restrictions. This is 
a de facto category, and not recognized by the 
FDA.
Over-the-counter Approved as a nonprescription drug by the FDA.
Abbreviation: FDA, US Food and Drug Administration.
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Table 3 States allowing pharmacist prescribing of EC
State LNG UPA Legislative details
Alaskaa Yes Yes Pharmacists may initiate EC under a state BOP regulation, AAC 52.240, with a written protocol agreement between 
a pharmacist and physician. This is a broad policy, which does not specifically include or exclude EC.
Training: pharmacist-training requirements must be included in the collaborative practice agreement between the 
prescriber and the pharmacist, and approved by the state BOP.
Californiab Yes Yes Pharmacists may initiate EC for women of all ages under state BOP regulation CCR 16-1746. The pharmacist must 
provide the patient with a state BOP-approved EC fact sheet.
Training: completion of a minimum of 1 hour of accredited continuing education specific to EC.
Hawaiic Yes Yes Pharmacists may initiate EC under state BOP regulation HAR 16-95-130, with a written protocol agreement 
between a pharmacist and physician. UPA is not specifically included in this state’s EC protocol; however, “drugs 
approved for emergency contraception are not limited to this [protocol] list”. Hawaii BOP staff state that the 
current EC protocol appendix is under review.
Training: completion of an accredited training program that must include the following:
•	 protocol procedures (of the Hawaii BOP regulations listed above)
•	 management of the sensitive communications often encountered in EC
•	 providing service to minors
•	 quality assurance
•	 referral for additional services
•	 documentation
Mained Yes Yes Pharmacists may initiate EC under state BOP regulation MRS 32-12-13821, with a written protocol agreement 
between a pharmacist and physician. The pharmacist must provide the patient with a state BOP-approved fact 
sheet.
Training: completion of an accredited training program that must include the following:
•	 conduct of sensitive communications
•	 quality assurance
•	 referral to additional services
•	 documentation
Massachusettse Yes Yes Pharmacists may initiate EC under state BOP regulation 2006-1, with a written protocol agreement between a 
pharmacist and physician.
Training: completion of a minimum of 2 hours of accredited continuing education, which must include the 
following:
•	 referring patient for additional service and follow-up
•	 quality assurance
•	 proper documentation
New 
Hampshiref
Yes Yes Pharmacists may initiate EC under a state BOP regulation, 318:16-a, with a written protocol agreement between a 
pharmacist and physician. This is a broad policy, which does not specifically include or exclude EC.
Training: pharmacist-training requirements depend on the service provided, and must be included in the 
collaborative practice agreement between the prescriber and the pharmacist and approved by the state BOP.
New Mexicog Yes No A section of the current state BOP regulation, NMAC 16.19.26.10 of the Pharmacist Prescriptive Authority Act 
allows pharmacists to “issue a prescription for emergency contraceptives”. However, the protocol does not include 
UPA. New Mexico Board of Pharmacy staff state that a new hormonal contraception protocol is under review, 
which includes a proposal for UPA.
Training: NA
Vermonth No No Notes: Previous state BOP regulations that allowed pharmacists to initiate EC, VSA 26.036.2077–2079, expired May 
2015. Pharmacists are no longer permitted to initiate prescription-only EC under a protocol in this state.
Training: NA
Washingtoni Yes Yes Pharmacists may initiate EC under state BOP regulation WAC 246-863-100, with a written protocol agreement 
between a pharmacist and physician. This is a broad policy, which does not specifically include or exclude EC.
Training: requirements must be included in the collaborative practice agreement between the prescriber and the 
pharmacist, and approved by the state BOP.
Notes: Regulations can be found at: ahttps://www.commerce.alaska.gov/web/cbpl/professionallicensing/boardofpharmacy.aspx; bhttp://www.pharmacy.ca.gov/laws_regs/
lawbook.pdf; chttp://cca.hawaii.gov/pvl/boards/pharmacy; dhttp://www.maine.gov/pfr/professionallicensing/professions/pharmacy/contactus.html; ehttp://www.mass.gov/eohhs/
gov/departments/dph/programs/hcq/dhpl/pharmacy/licensing/e-mail-the-board.html; fhttps://www.nh.gov/pharmacy/aboutus/staff.htm; ghttp://www.rld.state.nm.us/boards/
pharmacy.aspx; hhttps://www.sec.state.vt.us/professional-regulation/list-of-professions/pharmacy/board-members.aspx; ihttp://www.doh.wa.gov/aboutus/programsandservices/
healthsystemsqualityassurance/contactus.
Abbreviations: EC, emergency contraception; LNG, levonorgestrel; UPA, ulipristal acetate; BOP, Board of Pharmacy; NA, not applicable; AAC, Alaska Administrative 
Code; CCR, California Code of Regulations; HAR, Hawaii Administrative Rules; MRS, Maine Revised Statutes; NMAC, New Mexico Administrative Code; VSA, Vermont 
Statues Annotated; WAC, Washington Administrative Code.
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product to OTC in 2003. It took several years to overcome 
politically charged hurdles before approval was obtained in 
2006 for OTC status for women and men aged 18 years and 
older with government-issued identification.11
With the 2006 FDA approval of brand levonorgestrel for 
OTC sales for consumers aged 18 years and older, the medica-
tion itself was kept behind the pharmacy counter and required 
a visit to a pharmacy and an interaction with a pharmacy 
employee to purchase it. In addition, government-issued photo 
identification was required to prove the age of the consumer. 
In 2009, following a federal court case, the minimum age to 
obtain EC OTC was lowered from 18 to 17 years. Ultimately, 
after another legal challenge, in 2013 the FDA removed the age 
restriction. See Figure 1 for a timeline of levonorgestrel EC.
Before levonorgestrel EC became available OTC, multiple 
states (Alaska, California, Hawaii, Maine, Massachusetts, 
New Hampshire, New Mexico, Vermont, and Washington) 
passed legislation allowing pharmacists to prescribe EC 
and improve access. Since this time, New Hampshire and 
Vermont have allowed their legislation to expire; however, 
the authority may be incorporated into future legislative 
proposals for pharmacist prescribing of hormonal contracep-
tives. Pharmacist prescribing of EC enabled pharmacists who 
underwent additional training under individual collaborative 
or statewide protocols to prescribe and dispense EC directly 
to patients. Studies examining availability of and access to EC 
through pharmacist prescribing have shown variable results 
and persistent barriers to access, in particular for adolescents.
A study in California found that English- and Spanish-
speaking adolescents who called pharmacies listed as par-
ticipating in pharmacist prescribing of EC (listings on www.
ec-help.org) inquiring about anything that could be taken after 
unprotected sex to prevent pregnancy were told to come in to 
obtain EC 48% and 28% of the time, respectively.12 A 2012 study 
found that although EC was available at a majority of pharmacies 
(80%), adolescent mystery callers posing as 17-year-olds were 
only given the correct information about age requirements half 
the time, and misinformation was more common in low-income 
neighborhoods.13 More recent studies have also shown persistent 
barriers to access. A minority (20%) of Colorado pharmacies 
had EC in stock and on the shelf in 2014.14 A study published 
in 2016 that examined availability and access in community 
pharmacies in Wyoming showed that although 88% of pharma-
cies stocked EC, only 16% had it in stock and on the shelf.15
While levonorgestrel EC pills have been available with a 
prescription for over 15 years, multiple studies have shown 
that physician knowledge and prescribing of EC is not ideal 
and there is an opportunity for pharmacists to fill the gaps. A 
recent national multispecialty survey found that while 95% of 
health care providers had heard of levonorgestrel, providing 
it to patients was not as common. Family medicine (69%) 
and emergency medicine (74%) providers self-reported 
higher rates of providing levonorgestrel to their patients 
when compared to internal medicine (42%) and pediatrics 
(55%).16 Studies of pediatric emergency department provid-
ers have shown further evidence of knowledge deficits and 
underutilization of EC in emergency department settings.17,18 
A survey of family medicine physicians found that in 1 year, 
an average of 3.3 EC prescriptions were written and only 63% 
correctly answered the question regarding the timeframe in 
which EC should be taken.19 A national survey of obstetri-
cian–gynecologists found that only half (51%) offered EC 
to all women and a small proportion (6%) never offered it 
or only offered it after sexual assault (6%).20
Figure 1 History of levonorgestrel EC. Data from65,66
Abbreviations: EC, emergency contraception; FDA, US Food and Drug Administration; OTC, over-the-counter.
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Though pharmacists are accessible providers for patients 
seeking information and care regarding EC, some pharma-
cists also have knowledge deficits regarding levonorgestrel 
EC. Past reports in the media and medical literature have 
described pharmacists as uneducated regarding EC and 
unwilling to dispense or stock EC.21–25 However, as levo-
norgestrel EC availability has grown, so has pharmacist 
knowledge and awareness increased. Other literature has 
been published showing pharmacists as more educated and 
engaged in the provision of levonorgestrel EC.26–28
Pharmacists as accessible health care providers should 
be knowledgeable regarding different methods of EC. 
One study found that the most important predictor of 
pharmacists’ dispensing EC was individual pharmacists’ 
understanding correct information about EC, particularly 
mechanism of action.29 Recent regulatory status changes, 
including the elimination of a minimum age for OTC 
sales of levonorgestrel EC, make the pharmacist’s role in 
provision of EC education to patients more crucial than 
before. Studies have shown that a brief pharmacist-driven 
counseling session about EC had a positive effect on 
patients’ knowledge of EC and that EC counseling is fea-
sible in a retail pharmacy setting.30,31 Given the influence 
that pharmacists may have on educating patients regarding 
EC, pharmacists should understand and be able to counsel 
on the proper use, side effects, advanced provision, and 
effectiveness of EC.
Women presenting within 120 hours of unprotected inter-
course should be offered EC. There is some debate regarding 
possible decreased effectiveness of levonorgestrel in women 
with a body mass index (BMI) of 25 kg/m2 or greater.9,32.33 
The FDA is asking for more data, and at this time has not 
recommended any labeling changes for levonorgestrel EC 
in women with higher BMI. There are some recommenda-
tions, however, regarding women with BMI >25 that include 
referrals for UPA or copper intrauterine device (IUD) and 
for those with a BMI >35 to be referred to a trained provider 
for a copper IUD, if accessible in a timely fashion. Women 
with higher BMI should not be denied levonorgestrel or UPA 
EC, but should be made aware of the possible decrease in 
effectiveness and referred for optimal pregnancy prevention.9
Ulipristal acetate
The availability of OTC levonorgestrel has opened the 
door for other prescription EC products to be available via 
pharmacist prescribing, such as UPA, known by the brand 
name Ella (Afaxys Inc, Charleston, SC, USA). This form 
of EC works as a progestin receptor antagonist, delaying or 
 inhibiting ovulation when taken.34,35 UPA is a 30 mg tablet 
that is taken once within 120 hours after unprotected sex to 
prevent pregnancy. Given its different mechanism of action 
compared to levonorgestrel EC, its efficacy does not decrease 
with time. Therefore, it works equally well on day 1 after 
unprotected sex as it does on day 4.36
UPA was approved for use as EC in the US in August 
2010, and sales began in December of that year. However, 
in 2014 there were significant UPA access issues when the 
sole US distributor discontinued this product. The manufac-
turer then partnered with a new distributor.37 Unfortunately, 
as a result of this disruption in the supply chain, there was 
approximately 1 year where major drug wholesalers were 
unable to obtain and distribute UPA to retail pharmacies.38 
The resulting shortage likely slowed integration of this prod-
uct in clinical practice, because even if patients were able to 
obtain a prescription, they were unable to fill their prescrip-
tion at the pharmacy. Additionally, while the company did 
promote UPA to health care providers once it was readily 
available through the supply chain again, it is reasonable 
to assume that some providers and patients were or still are 
unaware that UPA is again available in pharmacies.38
Ultimately, there are many factors that play into pharmacy-
stocking practices, but lack of consumer demand for a product is 
likely a significant component. A 2016 study demonstrated that 
the majority of clinicians were unfamiliar with UPA as EC, with 
only 50% of reproductive health providers and 15% of emer-
gency medicine providers reporting that they were familiar with 
UPA.16 Additionally, if patient and providers demand is low, it is 
less likely that the drug will be readily stocked in pharmacies. In 
a mystery caller study conducted in Hawaii in 2013–2014, 198 
pharmacies were called and only 2.6% of pharmacies had UPA 
immediately available, although an additional 22.8% reported 
ability to order UPA and 82% had levonorgestrel in stock.39 
Another study conducted by Brant et al in Massachusetts in 
2013 used a mystery caller to determine availability of Ella in 
100 community pharmacies, of which 89% had levonorgestrel 
EC in stock compared to only 7% of pharmacies that had UPA 
in stock.40 This disparity in EC product availability may be 
related in part to the previous disruption to the UPA supply 
chain.39 In summary, these data suggest that although UPA is 
more effective than levonorgestrel as EC, most clinicians are 
not prescribing and may not be aware of UPA EC, and it is 
rarely immediately available in the pharmacy.
UPA remains prescription only, and seven states allow 
pharmacists to prescribe it under a collaborative practice 
agreement or statewide protocol. It is also available through 
several telemedicine providers and online pharmacies. These 
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online providers do not require a face-to-face visit with a 
providers to obtain a prescription; instead, the patient is asked 
specific screening questions and the online pharmacy collabo-
rates with a licensed prescriber and pharmacist to prescribe, 
fill, and ship UPA to the patient’s home.41,42 However, these 
online pharmacies are unable to ship to certain states.42 Pur-
chase from an online provider may be slightly more expensive, 
but may still be a valuable resource for many patients who are 
otherwise unable to access EC. This option is best for those 
who want to keep EC on hand for future use, rather than urgent 
use following an act of unprotected intercourse.
Lastly, studies have found that pharmacists may also 
benefit from additional training regarding UPA for EC. The 
Massachusetts study revealed that pharmacy staff members 
often provided incorrect information regarding UPA EC, as 
only 25% were able to identify Ella was the superior oral EC 
product 72–120 hours after intercourse.40 Regarding EC in 
general, only 21% of pharmacy staff gave completely medi-
cally accurate information, while 30% gave a “mixture of 
accurate and inaccurate” information and 34% gave “mostly 
inaccurate” information.40
Copper IUDs
Nonhormonal copper-containing IUDs have been used for 
EC for at least 40 years.43 In the US, the copper IUD has 
been available since 1988. Contraception is effective imme-
diately after IUD placement.44 The most commonly reported 
adverse effects associated with this IUD are abnormal men-
strual bleeding and increased frequency and/or intensity of 
cramps and pain. The benefit of using this method of EC is 
the continued contraception, which lasts 10 years, although 
evidence suggests that copper IUDs are highly effective up to 
12 years.45 Although progestin-releasing hormonal IUDs are 
available (Mirena®, Skyla®, Liletta®, and Kyleena®), none 
of these has been studied as EC. There has been one study 
evaluating pregnancy rates after the use of levonorgestrel EC 
and concomitant placement of a levonorgestrel IUD following 
unprotected intercourse.46
Various mechanisms of action have been suggested for 
the IUD. Prefertilization effects, including decreased sperm 
motility and viability, change in the speed of ovum trans-
port, and damage or destruction of the ovum, are the likely 
mechanisms of the copper IUD.47 Postfertilization effects 
including damage and/or destruction of the fertilized ovum 
are additional possible mechanisms.48 Both prefertilization 
and postfertilization effects occur prior to implantation.44
A systematic review reported that copper IUDs are the 
most effective method of EC, with a failure rate of less than 
one per thousand.49 This compares favorably to the reported 
failure rates of UPA and levonorgestrel. Unlike other methods 
of EC, the efficacy of the copper IUD appears to be unaf-
fected by the user’s BMI, time of menstrual cycle at insertion 
(after a negative urine pregnancy test), or additional acts of 
unprotected intercourse after placement.50 In addition to its 
superior efficacy, the IUD does not require ongoing efforts 
for proper use either.
The costs of IUDs have been a barrier to their use, for 
both patients and providers. Prices for an IUD typically range 
between US$500 and $1,000, in addition to provider visits 
for insertion, removal, and confirmation that the device was 
properly placed.51 While many insurance plans have covered 
IUDs for years, prior to passage of the Affordable Care Act 
(ACA), women were likely to have out-of-pocket charges 
for the product and the associated visits. The ACA mandates 
coverage for the copper IUD without cost sharing. The ACA 
has eliminated these costs for many women. It remains to be 
seen if the ACA leads to increases in the use of the copper 
IUD as a form of contraception, including EC.52 The phar-
macist’s role pertaining to the copper IUD as EC is primarily 
in providing comprehensive counseling to women so they are 
aware of all of their options, as well as providing referrals 
to providers who can provide same-day or timely insertions.
Little is known about pharmacists’ knowledge of copper 
IUDs as EC; however, several studies have reported miscon-
ceptions of other health care providers regarding IUDs. A 
2013 survey found that 33% of obstetrician–gynecologists 
who provide IUD services believed that this method of con-
traception is inappropriate for nulliparous women, and 57% 
believed IUDs should not be used in adolescents.53 Further, 
this study found that 26% of participants did not agree that 
the copper IUD can be used as EC.53 Currently, both the 
American College of Obstetricians and Gynecologists and 
the American Academy of Pediatrics promote IUD use as a 
first-line contraceptive option for all women, including young 
women and those who have never been pregnant.54,55 There is 
an inverse relationship between the effectiveness of various 
EC methods and pharmacist involvement, where pharmacists 
have the largest role with levonorgestrel.
Future prospects
Payment for pharmacist services
As the scope of practice for delivering clinical services 
expands for pharmacists, payment for the provision of these 
services must be received and models for payment sustain-
able. In a recent systematic review of payment to pharma-
cists for patient care, a majority (73%) of compensated or 
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 remunerated clinical services were paid for by government 
agencies, with the remainder funded by private insurance 
plans.56 This highlights the importance of obtaining support 
at the federal level for payment of pharmacist EC services, 
such as patient visits where EC is prescribed. The concept 
of payment for chronic care-management services has been 
addressed by the Centers for Medicare and Medicaid Ser-
vices, but clarity for EC services has not been provided.57
Given that services for EC may not typically involve full 
medication review (or comprehensive medication manage-
ment), time-dependent reimbursement may be most appro-
priate. This time would include screening and counseling to 
identify the most appropriate EC method, instructing patients 
about the proper use of EC, and potential discussion of 
routine contraceptive methods. In 2014, an evaluation of 60 
remunerated pharmacist clinical care programs worldwide 
indicated time-dependent fees were reimbursed at $93.60 
per hour.56
Pharmacy education to include advance 
provision
Pharmacists must have the knowledge and confidence to 
provide information to patients regarding various methods of 
EC, their effectiveness, and how to use them properly. Studies 
have demonstrated gaps in pharmacist knowledge that may 
result in incorrect information or advice given to patients 
seeking EC.15,58,59 Furthermore, education is needed to allow 
access to EC in a timely manner.15,60 In one small study, edu-
cating pharmacists about the use of the copper IUD for EC 
increased referral and uptake by women of the copper IUD 
almost threefold.61 Suggestions to improve knowledge and 
behavior include standardized protocols at the community 
pharmacy when patients are seeking EC, updated training 
(eg, continuing professional education) of pharmacists, and 
mandatory private consultation areas to enhance the counsel-
ing environment. These types of educational initiatives have 
the potential to reduce unintended pregnancies now and in 
the future.
Additionally, advance provision of EC may increase 
timely use. Pharmacists should be educated to inform women 
and men of having EC available prior to occasions when 
sexual intercourse is unprotected or underprotected. EC can 
be purchased online for privacy and at low cost, but is not 
a viable option for immediate use. Furthermore, caution 
should be used with online purchases, as EC products may 
be fraudulent. In a systematic review of 17 articles, any use 
of EC pills was found to be two to seven times greater among 
women who received an advance supply of EC pills. However, 
four randomized controlled trials did not show a significant 
reduction in unintended pregnancy over 12 months when 
advance provision was compared with standard provision of 
EC (risk ratio =0.9, 95% confidence interval: 0.69–1.18).62
Legislation to expand access in 
pharmacies
Since the late 1990s, individual states have taken different 
paths to expand access to EC.63 In the early stages of access, 
it was limited to women who had been sexually assaulted. 
Whereas levonorgestrel EC is now available OTC, UPA 
remains available by prescription only. Although access 
to oral EC has expanded in many ways, access remains 
restrictive in some areas. Legislation to expand pharmacist-
prescribing authorities in individual states can help increase 
access to both OTC and prescription EC products. Some 
states have regulations for pharmacists’ (or pharmacies’) right 
to refusal based on moral or ethical grounds. Legislation at 
the state level can ensure patient access is prioritized while 
respecting individual beliefs whenever possible.
Pharmacist counseling practices
Community pharmacists can help promote IUD use for EC 
by providing accurate information, dispelling myths, such 
as increased risk of pelvic inflammatory disease (associ-
ated with the no longer-available Dalkon Shield), and 
counseling about the risks and benefits. Pharmacists can 
further help by being familiar with local providers that can 
place IUDs in a timely manner. The aforementioned UK 
pilot program, in which trained community pharmacists 
evaluated women for EC IUD eligibility and referred if 
appropriate nearly, tripled the uptake of this EC method.61 
Community pharmacists in the US are in a prime position 
to provide EC counseling. Given its safety, efficacy, and 
cost-effectiveness, the copper IUD should be included in all 
discussions of possible EC options if feasible and appropri-
ate. See Table 4 for counseling points for EC.
Conclusion
Use of EC is increasing over time, due to the wider avail-
ability and accessibility of EC methods. Levonorgestrel EC is 
available OTC without any restriction. Further, in eight states, 
pharmacists are able to prescribe and provide oral EC directly 
to women. Pharmacists play a critical role to access to EC in 
community pharmacies by ensuring product availability in 
the inventory, up-to-date knowledge, and patient counseling. 
There are opportunities to expand access to EC in pharmacies 
further by implementing legislation expanding pharmacist 
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scope of practice, ensuring third-party reimbursement for 
clinical services delivered by pharmacists, and including EC 
in pharmacy education and training.
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